Search

Search Results

1. Pharmacotherapy of Epilepsy

   This article discusses seven newly available antiepileptic drugs (AEDs) and agents in phase III development.

   Lacosamide, licensed as an adjunctive...

   Linda J. Stephen, Martin J. Brodie in CNS Drugs

   Article 01 February 2011
   

2. Treatment Options in Juvenile Myoclonic Epilepsy

   Juvenile myoclonic epilepsy (JME) is characterized by excellent response to treatment, if diagnosed correctly. Lifestyle advice is an integral part...

   Laura Mantoan, Matthew Walker in Current Treatment Options in Neurology

   Article 15 April 2011

3. Epilepsy in the cancer patient

   Purpose

   Epileptic seizures in patients with malignancies usually occur as a consequence of brain metastases from systemic cancer or the presence of a...

   Odysseas Kargiotis, Sofia Markoula, Athanasios P. Kyritsis in Cancer Chemotherapy and Pharmacology

   Article 09 February 2011
   

4. „Target“-Mechanismen der Pharmakoresistenz bei Epilepsiepatienten

   Antiepileptic therapy is aimed at the suppression of pathological neuronal synchronization. The drug targets of antiepileptic drugs (AEDs) are mostly...

   H. Beck, M. Uebachs in Zeitschrift für Epileptologie

   Article 17 July 2010

5. Levetiracetam in Childhood Epilepsy

   Levetiracetam is an antiepileptic drug that has been shown to be effective in various types of seizures, both partial and generalized. Although it is...

   Alberto Verrotti, Ebe D’Adamo, ... Paolo Curatolo in Pediatric Drugs

   Article 01 June 2010
   

6. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

   The aim of this study was to assess the efficacy, safety and tolerability of the antiepileptic compound levetiracetam (LEV) for the treatment of...

   Martin Wolz, Matthias Löhle, ... Alexander Storch in Journal of Neural Transmission

   Article 29 August 2010
   

7. Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges

   Background

   In tuberous sclerosis complex (TSC), a substantially increased risk of develo** epilepsy is present as a result of a disruption of a TSC...

   Romina Moavero, Caterina Cerminara, Paolo Curatolo in Child's Nervous System

   Article 01 April 2010

8. Treatment of Tics and Tourette Syndrome

   Tics come in a variety of types and frequencies; have a waxing and waning course; are exacerbated by stress, anxiety, and fatigue; and often resolve...

   Harvey S. Singer in Current Treatment Options in Neurology

   Article 10 September 2010

9. Welche Faktoren beeinflussen die Serumkonzentration von Levetiracetam?

   We evaluated factors possibly influencing serum concentrations of levetiracetam (LEV-SC). The study included 163 patients with epilepsy (91 men, 72...

   J. Bauer, C. Pfeiffer, W. Burr in Der Nervenarzt

   Article 30 January 2010
   

10. Piracetam and Piracetam-Like Drugs

    There is an increasing interest in nootropic drugs for the treatment of CNS disorders. Since the last meta-analysis of the clinical efficacy of...

    Andrei G. Malykh, M. Reza Sadaie in Drugs

    Article 01 February 2010
    

11. New molecular targets for antiepileptic drugs: α₂δ, SV2A, and K_v7/KCNQ/M potassium channels

    Many currently prescribed antiepileptic drugs (AEDs) act via voltage-gated sodium channels, through effects on γ-aminobutyric acid-mediated...

    Michael A. Rogawski, Carl W. Bazil in Current Neurology and Neuroscience Reports

    Article 01 July 2008

12. Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases

    Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative...

    Tibor Kovács, Marianna Farsang, ... Anita Kamondi in Journal of Neural Transmission

    Article 12 September 2009
    

13. Levetiracetam voor neurologische en psychiatrische aandoeningen

    M. L. Becker in Medisch-Farmaceutische Mededelingen

    Article 01 July 2009

14. The evolution of antiepileptic drug development and regulation

    The early years of antiepileptic drug development were characterised by observation and serendipity, rather than a rational, targeted approach to...

    Alexis Arzimanoglou, Elinor Ben-Menachem, ... Miranda Harrison in Epileptic Disorders

    Article 01 March 2010

15. In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs

    The effects of nitric oxide-active drugs on the anticonvulsant action of the antiepileptic drug levetiracetam in an experimental model of partial...

    Pierangelo Sardo, Stefania D’Agostino, ... Giuseppe Ferraro in Journal of Neural Transmission

    Article 12 May 2009
    

16. Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment

    Excess neural activity in the CA3 region of the hippocampus has been linked to memory impairment in aged rats. We tested whether interventions aimed...

    Ming Teng Koh, Rebecca P Haberman, ... Michela Gallagher in Neuropsychopharmacology

    Article 23 December 2009
    

17. Antimigraine drugs: new frontiers

    There are many acute care and preventive medications for the treatment of migraine. However, patients may often find that their headaches are not...

    A. Rapoport in Neurological Sciences

    Article Open access 05 May 2009

18. Intravenous levetiracetam as treatment for status epilepticus

    There are established drugs for the treatment of status epilepticus (SE) but their potentially hazardous side-effects are well known. Levetiracetam...

    Sascha Berning, Frank Boesebeck, ... Christoph Kellinghaus in Journal of Neurology

    Article 15 May 2009

19. Pharmacological Management of Epilepsy

    There is still a need for new antiepileptic drugs (AEDs) as the clinical efficacy, tolerability, toxicity or pharmacokinetic properties of existing...

    Cecilie Johannessen Landmark, Svein I. Johannessen in Drugs

    Article 01 October 2008
    

20. Levetiracetam in stiff-person syndrome

    We studied the effects of oral levetiracetam (LEV) (500 mg twice daily) in three women with stiff-person syndrome in a single-blind,...

    GianPietro Sechi, Marianna Barrocu, ... Gian Franco Sau in Journal of Neurology

    Article 03 September 2008